<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Physostigmine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Physostigmine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Physostigmine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_pediatric" data-topicid="12703" href="/d/html/12703.html" rel="external">see "Physostigmine: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="15558" href="/d/html/15558.html" rel="external">see "Physostigmine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F209713"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor;</li>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F209696"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consultation with a clinical toxicologist or poison control center is recommended prior to use.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3ad312f-ef6d-4821-ae07-a9d8a1a807de">Reversal of toxic anticholinergic effects</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of toxic anticholinergic effects: Note:</b> When administering by IV injection, administer no more rapidly than 1 mg/minute to prevent bradycardia, respiratory distress, and seizures from too rapid administration. Slower administration (ie, over ≥5 minutes) may be preferable. The duration of action of some anticholinergic agents may exceed the duration of action of physostigmine; therefore, monitor closely for recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33403170','lexi-content-ref-Howland.1','lexi-content-ref-36575250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33403170','lexi-content-ref-Howland.1','lexi-content-ref-36575250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> Initial: 0.5 to 2 mg; may repeat every 10 to 30 minutes until response occurs. Generally, a single dose or a short duration of treatment (&lt;6.5 hours) is sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20405266','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20405266','lexi-content-ref-manu.1'])">Ref</a></span>); longer durations of therapy may be required to manage life-threatening anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33403170','lexi-content-ref-20229618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33403170','lexi-content-ref-20229618'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991328"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988679"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F209697"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F209709"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12703" href="/d/html/12703.html" rel="external">see "Physostigmine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3ad312f-ef6d-4821-ae07-a9d8a1a807de">Reversal of toxic anticholinergic effects</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of toxic anticholinergic effects:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for life-threatening situations only. Slow IV administration (≤0.5 mg/minute for pediatric patients) is required to prevent bradycardia, respiratory distress, and seizures. Slower administration (ie, over no less than 5 minutes) may be preferable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). The duration of action of some anticholinergic agents may exceed the duration of action of physostigmine; therefore, monitor closely for recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). Consultation with a clinical toxicologist or poison control center is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV: Initial: 0.02 mg/kg; maximum dose: 0.5 mg/dose; may repeat every 5 to 15 minutes until response occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Howland.1'])">Ref</a></span>); maximum total dose: 2 mg (total). Subsequent doses may be required to manage clinical relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). Based on adult experience, a short total duration of therapy (&lt;6.5 hours) is often adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20405266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20405266'])">Ref</a></span>). Higher cumulative doses or prolonged therapy may be necessary in some cases; in one case report, an 11-year-old initially responded to 1.5 mg of physostigmine for antimuscarinic delirium and agitation with a good response. As the physostigmine effects diminished, agitation returned, which was unresponsive to benzodiazepines and required 4 additional 1 mg doses of physostigmine administered over 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26383155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26383155'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153601"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153602"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F58074193"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<p style="text-indent:0em;">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia</p>
<p style="text-indent:0em;margin-left:2em;">Gastrointestinal: Nausea, salivation, vomiting</p>
<p style="text-indent:0em;margin-left:2em;">Nervous system: Seizures</p></div>
<div class="block adr drugH1Div" id="F209665"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, salivation, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizures</p></div>
<div class="block coi drugH1Div" id="F209681"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal or genitourinary obstruction; asthma; gangrene; diabetes; cardiovascular disease; any vagotonic state; coadministration of choline esters and depolarizing neuromuscular-blocking agents (eg, succinylcholine).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Physostigmine should not be used in the absence of toxicity from an anticholinergic agent (Howland 2019).</p></div>
<div class="block war drugH1Div" id="F209662"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Patient should have a normal QRS interval, as measured by ECG, in order to receive physostigmine; use caution in poisoning with agents known to prolong intraventricular conduction (Arens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholinergic effects: Symptoms of excessive cholinergic activity may occur (eg, salivation, urinary incontinence, defecation, vomiting). If excessive diaphoresis or nausea occurs, reduce subsequent doses. Atropine should be available to reverse cholinergic symptoms, if necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions may occur in patients with allergy to cholinesterase inhibitors or salicylates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure: Use with caution in patients with a known seizure disorder or coingestion of epileptogenic drugs. Risk of seizure activity increases with too rapid administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Products may contain sodium metabisulfite which may cause allergic reactions in some individuals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Administer no more rapidly than 1 mg/minute in adults or 0.5 mg/minute in children to prevent bradycardia, respiratory distress, and seizures from too rapid administration. Administration at an even slower rate (ie, over no less than 5 minutes) may be preferable (Howland 2019). Although the use of a continuous infusion of physostigmine has been described in the literature (Eyer 2008; Hail 2013; Phillips 2014; Wang 2021), the routine use of a continuous infusion is not recommended. A continuous infusion may be considered for patients with profound anticholinergic effects who require frequent doses of physostigmine. However, it is preferable to titrate physostigmine to patient needs through the use of intermittent administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tricyclic antidepressant (TCA) poisoning: Asystole and seizures have been reported when physostigmine was administered to TCA poisoned patients (Pentel 1980). Physostigmine is not recommended in patients with known or suspected TCA intoxication.</p></div>
<div class="block foc drugH1Div" id="F209674"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as salicylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (2 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F209658"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323686"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Physostigmine Salicylate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $46.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F209678"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse no more rapidly than 1 mg/minute. Too rapid administration may cause bradycardia, respiratory distress, and seizures. Slower administration (ie, over ≥5 minutes) may be preferable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). May also be administered IM (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613586"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: May administer as undiluted solution.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse undiluted solution slowly; maximum rate: Pediatric patients: 0.5 mg/minute; a higher maximum rate in adults: 1 mg/minute. Slower administration (ie, over ≥5 minutes) may be preferable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). Too rapid administration can cause bradycardia and hypersalivation leading to respiratory distress and seizures.</p></div>
<div class="block hazard drugH1Div" id="F49132658"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent; use appropriate precautions for handling and disposal (EPA, P-listed).</p></div>
<div class="block use drugH1Div" id="F209677"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Reversal of central nervous system anticholinergic syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The decision to use physostigmine should be made in consultation with a clinical toxicologist or poison control center, and the patient-specific risk-benefit ratio should always be considered. Physostigmine is most efficacious for agitation and/or delirium resulting from drugs with predominant anticholinergic properties (eg, atropine, benztropine, scopolamine, dimenhydrinate, diphenhydramine, oxybutynin), some plants from the <i>Solanaceae </i>family (eg, <i>Atropa belladonna</i> [deadly nightshade], jimson weed [<i>Datura</i> spp]), but may also be beneficial for other medications with anticholinergic effects (eg, atypical antipsychotics, cyclobenzaprine, hydroxyzine) (Arens 2018; Boley 2019a; Boley 2019b; Cole 2012; Dawson 2022; Grenga 2018; Khan 2021; Mullins 2022; Rasimas 2014; Wang 2021; Watkins 2015; Weizberg 2006; Whitledge 2023).</p></div>
<div class="block mst drugH1Div" id="F209722"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PHYSostigmine may be confused with Prostigmin, pyRIDostigmine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299877"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F209667"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13823806"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Limited outcome data following maternal use of physostigmine as an antidote following acute poisoning (Zelner 2015) or to reverse the effects of scopolamine administered during labor (Boehm 1997; Smiler 1973; Smith 1976) are available.</p>
<p style="text-indent:0em;margin-top:2em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block brc drugH1Div" id="F20128215"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if physostigmine is present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F209672"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">ECG, vital signs; consult individual institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The duration of action of some anticholinergic agents may exceed the duration of action of physostigmine; therefore, monitor closely for recurrence of symptoms (Blackstone 2020; Howland 2019; Whitledge 2022).</p></div>
<div class="block pha drugH1Div" id="F209661"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Physostigmine is a carbamate which inhibits the enzyme acetylcholinesterase and prolongs the central and peripheral effects of acetylcholine</p></div>
<div class="block phk drugH1Div" id="F209680"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Within 3 to 8 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: 45 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM: Readily absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely distributed throughout the body; crosses blood-brain barrier readily and reverses both central and peripheral anticholinergic effects</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Via hydrolysis by cholinesterases</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1 to 2 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038767"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Anticholium</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anticholium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anticholium</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anticholium | Physostigmin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Physostigmin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Anticholium | Anticholium life | Anticholium nordic prime | Anticholium specific | Anticholium unimedic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Antilirium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31414401">
<a name="31414401"></a>Arens AM, Kearney T. Adverse effects of physostigmine. <i>J Med Toxicol</i>. 2019;15(3):184-191. doi:10.1007/s13181-019-00697-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/31414401/pubmed" id="31414401" target="_blank">31414401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703024">
<a name="28703024"></a>Arens AM, Shah K, Al-Abri S, Olson KR, Kearney T. Safety and effectiveness of physostigmine: a 10-year retrospective review. <i>Clin Toxicol</i>. 2018;56(2):101-107. doi:10.1080/15563650.2017.1342828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/28703024/pubmed" id="28703024" target="_blank">28703024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B, "Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33403170">
<a name="33403170"></a>Blackstone NG, Olson A, Ainapurapu B. Physostigmine in anticholinergic poisoning: an old antidote with resurgence. <i>Cureus</i>. 2020;12(11):e11739. doi:10.7759/cureus.11739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/33403170/pubmed" id="33403170" target="_blank">33403170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22596">
<a name="22596"></a>Boehm FH, Egilmez A, Smith BE. Physostigmine's effect on diminished fetal heart rate variability caused by scopolamine, meperidine and propiomazine. <i>J Perinat Med</i>. 1977;5(5):214-222. doi:10.1515/jpme.1977.5.5.214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/22596/pubmed" id="22596" target="_blank">22596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29956570">
<a name="29956570"></a>Boley SP, Olives TD, Bangh SA, Fahrner S, Cole JB. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center. <i>Clin Toxicol</i>. 2019a;57(1):50-55. doi:10.1080/15563650.2018.1485154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/29956570/pubmed" id="29956570" target="_blank">29956570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31023063">
<a name="31023063"></a>Boley SP, Stellpflug SJ. A comparison of resource utilization in the management of anticholinergic delirium between physostigmine and nonantidote therapy. <i>Ann Pharmacother</i>. 2019b;53(10):1026-1032. doi:10.1177/1060028019846654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/31023063/pubmed" id="31023063" target="_blank">31023063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10736125">
<a name="10736125"></a>Burns MJ, Linden CH, Graudins A, et al, “A Comparison of Physostigmine and Benzodiazepines for the Treatment of Anticholinergic Poisoning,” <i>Ann Emerg Med</i>, 2000, 35(4):374-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/10736125/pubmed" id="10736125" target="_blank">10736125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21802878">
<a name="21802878"></a>Cole JB, Stellpflug SJ, Ellsworth H, Harris CR. Reversal of quetiapine-induced altered mental status with physostigmine: a case series. <i>Am J Emerg Med</i>. 2012;30(6):950-953. doi:10.1016/j.ajem.2011.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/21802878/pubmed" id="21802878" target="_blank">21802878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34705298">
<a name="34705298"></a>Dawson A. Physostigmine should be used more readily for antimuscarinic toxicity: PRO. <i>Br J Clin Pharmacol.</i> 2022;88(1):58-60. doi:10.1111/bcp.15120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/34705298/pubmed" id="34705298" target="_blank">34705298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18344110">
<a name="18344110"></a>Eyer F, Jetzinger E, Pfab R, et al, “Withdrawal from High-Dose Tranylcypromine,” <i>Clin Toxicol (Phila)</i>, 2008, 46(3):261-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/18344110/pubmed" id="18344110" target="_blank">18344110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20861718">
<a name="20861718"></a>Glatstein MM, Alabdulrazzaq F, Garcia-Bournissen F, Scolnik D. Use of physostigmine for hallucinogenic plant poisoning in a teenager: case report and review of the literature. <i>Am J Ther</i>. 2012;19(5):384-388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/20861718/pubmed" id="20861718" target="_blank">20861718</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Grenga PN, Schult RF, Wiegand TJ. Physostigmine use in clozapine intoxication from adulterated heroin: an atypical toxidrome with an effective antidote. <i>Toxicol Communications. </i>2018;2(1):53-55.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23473460">
<a name="23473460"></a>Hail SL, Obafemi A, and Kleinschmidt KC, “Successful Management of Olanzapine-Induced Anticholinergic Agitation and Delirium With a Continuous Intravenous Infusion of Physostigmine in a Pediatric Patient,” <i>Clin Toxicol (Phila)</i>, 2013, 51(3):162-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/23473460/pubmed" id="23473460" target="_blank">23473460</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Healthcare Environmental Resource Center (HERC). Pharmaceuticals—Hazardous Waste. http://www.hercenter.org/hazmat/pharma.cfm#listed. Published 2015. Accessed October 23, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.1">
<a name="Howland.1"></a>Howland MA. Antidotes in depth: physostigmine salicylate. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds.<i> Goldfrank's Toxicologic Emergencies. </i>11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jenike MA, Albert MS, Heller H, et al, “Oral Physostigmine Treatment for Patients With Presenile and Senile Dementia of the Alzheimer's Type: A Double-Blind Placebo-Controlled Trial,” <i>J Clin Psychiatry</i>, 1990, 51(1):3-7.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33880270">
<a name="33880270"></a>Khan A, Singh G, Jacob J. A rare presentation of anticholinergic toxicity in a young patient due to over-the-counter cold medicines. <i>Cureus</i>. 2021;13(3):e13919. doi:10.7759/cureus.13919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/33880270/pubmed" id="33880270" target="_blank">33880270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20229618">
<a name="20229618"></a>Krenzelok EP, “Aspects of <i>Datura</i> Poisoning and Treatment,” <i>Clin Toxicol</i>, 2010, 48(2):104-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/20229618/pubmed" id="20229618" target="_blank">20229618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34784063">
<a name="34784063"></a>Mullins ME. Physostigmine should be used more readily for antimuscarinic toxicity: CON. <i>Br J Clin Pharmacol</i>. 2022;88(1):61-63. doi:10.1111/bcp.15121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/34784063/pubmed" id="34784063" target="_blank">34784063</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  O'Donnell SJ, Burkhart KK, Donovan JW, et al, “Safety of Physostigmine Use for Anticholinergic Toxicity,” <i>J Toxicol Clin Toxicol</i>, 2002, 40(5):684.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7001962">
<a name="7001962"></a>Pentel P and Peterson CD, “Asystole Complicating Physostigmine Treatment of Tricyclic Antidepressant Overdose,” <i>Ann Emerg Med</i>, 1980, 9(11):588-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/7001962/pubmed" id="7001962" target="_blank">7001962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24798647">
<a name="24798647"></a>Phillips MA, Acquisto NM, Gorodetsky RM, Wiegand TJ. Use of a physostigmine continuous infusion for the treatment of severe and recurrent antimuscarinic toxicity in a mixed drug overdose. <i>J Med Toxicol</i>. 2014;10(2):205-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/24798647/pubmed" id="24798647" target="_blank">24798647</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Physostigmine injection [prescribing information]. Lake Forest, IL: Akorn Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Rasimas JJ, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. <i>J Amer Acad Emerg Psychiatr</i>. 2014;12:5-24.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20405266">
<a name="20405266"></a>Rosenbaum C, Bird SB. Timing and frequency of physostigmine redosing for antimuscarinic toxicity. <i>J Med Toxicol</i>. 2010;6(4):386-392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/20405266/pubmed" id="20405266" target="_blank">20405266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4707533">
<a name="4707533"></a>Smiler BG, Bartholomew EG, Sivak BJ, Alexander GD, Brown EM. Physostigmine reversal of scopolamine delirium in obstetric patients. <i>Am J Obstet Gynecol</i>. 1973;116(3):326-329. doi:10.1016/s0002-9378(15)31288-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/4707533/pubmed" id="4707533" target="_blank">4707533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7975">
<a name="7975"></a>Smith DB, Clark RB, Stephens SR, Sherman RL, Hyde ML. Physostigmine reversal of sedation in parturients. <i>Anesth Analg</i>. 1976;55(4):478-480. doi:10.1213/00000539-197607000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/7975/pubmed" id="7975" target="_blank">7975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26383155">
<a name="26383155"></a>Thornton SL, Farnaes L, Minns A. Prolonged antimuscarinic delirium in a child due to benztropine exposure treated with multiple doses of physostigmine. <i>Pediatr Emerg Care</i>. 2016;32(4):243-245. doi:10.1097/PEC.0000000000000503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/26383155/pubmed" id="26383155" target="_blank">26383155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33295809">
<a name="33295809"></a>Wang GS, Baker K, Ng P, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. <i>Clin Toxicol</i>. 2021;59(8):698-704. doi:10.1080/15563650.2020.1854281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/33295809/pubmed" id="33295809" target="_blank">33295809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25510306">
<a name="25510306"></a>Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME; Toxicology Investigators Consortium investigators. The use of physostigmine by toxicologists in anticholinergic toxicity. <i>J Med Toxicol</i>. 2015;11(2):179-184. doi:10.1007/s13181-014-0452-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/25510306/pubmed" id="25510306" target="_blank">25510306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16749552">
<a name="16749552"></a>Weizberg M, Su M, Mazzola JL, Bird SB, Brush DE, Boyer EW. Altered mental status from olanzapine overdose treated with physostigmine. <i>Clin Toxicol (Phila)</i>. 2006;44(3):319-325. doi:10.1080/15563650600584535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/16749552/pubmed" id="16749552" target="_blank">16749552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36575250">
<a name="36575250"></a>Whitledge JD, Watson CJ, Simpson M, et al. Diphenhydramine-induced antimuscarinic delirium treated with physostigmine and transdermal rivastigmine. <i>J Med Toxicol</i>. 2023;19(2):219-223. doi:10.1007/s13181-022-00925-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/36575250/pubmed" id="36575250" target="_blank">36575250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25783189">
<a name="25783189"></a>Zelner I, Matlow J, Hutson JR, et al; Toxicology Investigators Consortium (ToxIC). Acute poisoning during pregnancy: observations from the Toxicology Investigators Consortium. <i>J Med Toxicol</i>. 2015;11(3):301-308. doi:10.1007/s13181-015-0467-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/physostigmine-drug-information/abstract-text/25783189/pubmed" id="25783189" target="_blank">25783189</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9770 Version 194.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
